Selected Announcements: Q1 net profit of Qiangyi Co., Ltd. increased by 654.79%–761.6% year-on-year; Wuchan Zhongda plans to repurchase company shares worth 200 million to 400 million yuan

People’s Finance News, April 3. 【Operating Data】Qiangyi Co., Ltd.: net profit for Q1 is expected to increase 654.79%—761.6% year over year. Dongyue Silicon Materials: net profit for Q1 is expected to increase 397.02%—451.34% year over year. Jin Qilin: in 2025, net profit increased 47.95% year over year; plans to distribute 10 per 10 shares for 4.5 yuan. Xingsu Electronics: in 2025, net profit increased 12.16% year over year; plans to distribute 10 per 10 shares for 4.3 yuan. Keli Equipment: in 2025, net profit increased 3.33% year over year; plans to convert 10 shares to 3 shares and distribute 10 per 10 shares for 10 yuan. Miaocai Blueberry performance quick report: net profit for Q1 2026 decreased 8.3% year over year. Aijingshi: in 2025, net profit decreased 23.45% year over year; plans to distribute 10 per 10 shares for 2.53 yuan. Chuanjinno: net profit for Q1 is expected to decrease 33.35%—47.24% year over year. Feilong Co., Ltd.: net profit for Q1 is expected to decrease 42.92%—59.23% year over year. Hunan Investment: in 2025, net profit decreased 48.33% year over year; plans to distribute 10 per 10 shares for 0.3 yuan. Country Garden Holdings: in 2025, loss was 132.81 billion yuan. Benxi Steel Plate: in 2025, loss was 39.42 billion yuan. Jianghuai Automobile: in 2025, loss was 17.03 billion yuan. *ST Langyuan: in 2025, loss was 14.971 million yuan. Huayang New Materials performance quick report: in 2025, loss was 5.7034 million yuan. Bozhong Precision Machinery: as of March 31, the company’s total outstanding orders were 6.634 billion yuan, up 163.78% year over year. Shanghai Port Group: in March, it expects to complete container throughput of 4.692 million TEUs, up 8.8% year over year. *ST Tianshan: sold 540 head of live breeding animals in March; sales revenue was 7.9852 million yuan.

【Hot Topics】Tianjin Yao Medicine: the company’s R&D is mainly based on generic drugs, with no innovative drug projects currently under development. Xinghui Huancai: if raw material prices fluctuate sharply, the company may not be able to effectively defuse cost pressure through conventional cost transfer mechanisms. Shuangta Foods: the EU has initiated an anti-dumping investigation into China’s pea protein; for the company’s implicated products, the applicable anti-dumping duty rate is 112.7%. Deko Li: the company’s optical switching (OCS) products have not yet obtained bulk orders from overseas mainstream manufacturers. Helin Micro: has re-submitted its application to the Hong Kong Exchanges and Clearing Limited for the issuance and listing of H shares.

【Refinancing】Lepao Hi-Tech: plans to raise funds via a private placement of not more than 2.5 billion yuan. Yu Guang Gold and Lead: plans to raise funds via a private placement to controlling shareholders and others of not more than 1.839 billion yuan. Aben Chemistry: plans to raise funds via a private placement of not more than 1.005 billion yuan. Gaole Shares: plans to raise targeted funds via a private placement of not more than 854 million yuan, to be used to supplement working capital.

【Increase/Decrease Holdings, Repurchases】Huachan Zhongda: plans to repurchase 200 million—400 million yuan worth of company shares. NovaStar Nebula: plans to repurchase 50 million—100 million yuan worth of company shares. Colins Electric: shareholders and directors plan to jointly reduce their holdings of the company’s shares by no more than 3%. Molding Technology: the controlling shareholder plans to reduce its holdings of the company’s shares by no more than 3%. Mingxin Xuteng: shareholders Mingxin Assets plan to reduce their holdings of the company’s shares by no more than 2%.

【Winning Bid Contracts】Xizi Clean Energy: the company won a procurement bid worth 63.45 million yuan. Wenke Shares: signed a 50.8162 million yuan landscape engineering construction contract with Shenzhen Bay Area Urban Construction and Development Co., Ltd.

【Major Investment】Xingfa Group: plans to invest 1.381 billion yuan to build a 100,000-ton-per-year battery-grade lithium iron phosphate project. Inyng Electronics: plans to raise targeted funds from its controlling shareholder of not more than 1.0 billion yuan, to be used for R&D and industrialization of mixed-signal chips, etc. Yunnan Germanium Industry: a controlling subsidiary plans to implement the “high-quality indium phosphide single-crystal wafer construction project.” Jushen Shares: plans to invest in building a comprehensive logistics warehousing project.

【Other】China Minmetals Shares: a controlling subsidiary, Dairui Mining, has obtained an environmental feasibility approval. Zhuhai Zhongfu: the controlling shareholder will be changed to Hengqin Xingying; the stock resumes trading. *ST Jinglun: the company’s stock has touched forced delisting indicators related to trading; trading will be suspended. Xianhe Shares: one of the actual controllers, Wang Minglong, received a filing notice from the China Securities Regulatory Commission. *ST Guandian: the company has been filed for alleged violations of information disclosure laws and regulations. *ST Jinbi: Hanfei Investment’s performance commitment party has received the “Decision on Administrative Regulatory Measures” from the Guangdong Securities Regulatory Bureau. E-C Digital: due to alleged violations of information disclosure laws and regulations, the company has been filed for investigation.

Bogi Biomedical: the clinical trial of Danyuan Tangbi Ointment has been approved. Tai’enkang: received the drug registration certificate for Moxitingdan tablets. Gan Li Pharmaceutical: GLR2037 tablets Phase I clinical trial has completed dosing for the first subject. Xinhua Pharmaceutical: obtained a drug registration certificate for a concentrated solution of sodium, potassium, magnesium, and calcium for injection. Teiyi Pharmaceutical: obtained the drug registration certificate for glucosamine sulfate capsules. Runzhou Shares: obtained the drug registration certificate for norepinephrine hydrochloride injection. Meicang Biotechnology: obtained medical device registration for a kit for measuring glucose-6-phosphate dehydrogenase. Huahai Pharmaceuticals: mesalamine enteric-coated tablets obtained a drug registration certificate. KonTai Biotech: obtained a drug registration certificate for an adsorbed tetanus-diphtheria vaccine. China National Medicines Modern: left-arnine injection obtained a drug registration certificate. Xingqi Eye Drops: obtained a drug registration certificate for brommopride tartrate ophthalmic drops.